HomeCompareBBIXF vs SBUX

BBIXF vs SBUX: Dividend Comparison 2026

BBIXF yields 1666.67% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBIXF wins by $1839785666.09M in total portfolio value
10 years
BBIXF
BBIXF
● Live price
1666.67%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1839785666.26M
Annual income
$1,645,561,548,268,653.00
Full BBIXF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — BBIXF vs SBUX

📍 BBIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBIXFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBIXF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBIXF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBIXF
Annual income on $10K today (after 15% tax)
$141,666.67/yr
After 10yr DRIP, annual income (after tax)
$1,398,727,316,028,355.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, BBIXF beats the other by $1,398,727,315,967,889.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBIXF + SBUX for your $10,000?

BBIXF: 50%SBUX: 50%
100% SBUX50/50100% BBIXF
Portfolio after 10yr
$919892833.21M
Annual income
$822,780,774,169,894.80/yr
Blended yield
89.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

BBIXF
No analyst data
Altman Z
-19.8
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBIXF buys
0
SBUX buys
0
No recent congressional trades found for BBIXF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBIXFSBUX
Forward yield1666.67%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$1839785666.26M$167.0K
Annual income after 10y$1,645,561,548,268,653.00$71,136.45
Total dividends collected$1825787439.21M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: BBIXF vs SBUX ($10,000, DRIP)

YearBBIXF PortfolioBBIXF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$177,367$166,666.67$11,121$420.68+$166.2KBBIXF
2$2,952,503$2,762,720.66$12,548$648.40+$2.94MBBIXF
3$46,139,686$42,980,507.73$14,440$1,013.98+$46.13MBBIXF
4$677,098,258$627,728,794.51$17,068$1,617.30+$677.08MBBIXF
5$9,333,745,461$8,609,250,324.41$20,912$2,649.52+$9333.72MBBIXF
6$120,900,966,251$110,913,858,608.07$26,875$4,499.29+$120900.94MBBIXF
7$1,472,054,345,780$1,342,690,311,890.92$36,771$8,014.12+$1472054.31MBBIXF
8$16,853,789,214,559$15,278,691,064,574.45$54,542$15,197.11+$16853789.16MBBIXF
9$181,517,867,281,133$163,484,312,821,554.84$89,602$31,242.49+$181517867.19MBBIXF
10$1,839,785,666,259,465$1,645,561,548,268,653.00$167,011$71,136.45+$1839785666.09MBBIXF

BBIXF vs SBUX: Complete Analysis 2026

BBIXFStock

Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone trauma and arthritis. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large and segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.

Full BBIXF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this BBIXF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBIXF vs SCHDBBIXF vs JEPIBBIXF vs OBBIXF vs KOBBIXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.